title: Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.
authors.affiliation: Medical Clinic III for Oncology, Haematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Mayer
authors.affiliation: Institute of Neuropathology, University Hospital Bonn (UKB), Bonn, Germany.
authors.forename: G H
authors.initials: GH
authors.lastname: Gielen
authors.affiliation: Department of Radiology, University Hospital Bonn (UKB), Bonn, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Willinek
authors.affiliation: Medical Clinic III, University Hospital Mannheim, Mannheim, Germany.
authors.forename: M C
authors.initials: MC
authors.lastname: Müller
authors.affiliation: Medical Clinic III for Oncology, Haematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Wolf
mesh_terms: D002545:Brain Ischemia / Q000139:chemically induced*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011724:Pyridazines / Q000009:adverse effects*
chemical_list: D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl